3 completed, 2 terminated, 1 unknown. 3 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Unknown 1 |
Follow IMO-2055: new trials by email Literature Review of IMO-2055 trials Research Report on IMO-2055
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study IR103 - HIV | Phase 3 | Unknown | Immune Response BioPharma, Inc. | 500 | 2017-06-01 | 2016-02-23 |
| EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck EMD 1201081 + 5-FU + Cisplatin + Cetuximab - Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Terminated | Merck KGaA, Darmstadt, Germany | 13 | 2010-08-01 | 2014-06-17 |
| EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cetuximab, EMD 1201081 - Squamous Cell Carcinoma of the Head and Neck Cancer | Phase 2 | Completed | EMD Serono | 107 | 2009-12-01 | 2017-01-30 |
| Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer IMO-2055, Cetuximab, FOLFIRI - Colorectal Cancer | Phase 1 | Terminated | EMD Serono | 21 | 2009-01-01 | 2013-10-22 |
| Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC IMO-2055 - Non-Small Cell Lung Cancer | Phase 1 | Completed | EMD Serono | 36 | 2007-11-01 | 2013-10-22 |
| Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma IMO-2055 - Renal Cell Carcinoma | Phase 2 | Completed | Idera Pharmaceuticals, Inc. | 92 | 2004-06-01 | 2018-06-12 |
Neoplasm Metastasis (4) · Recurrence (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
EMD Serono (3) · Idera Pharmaceuticals, Inc. (1) · Immune Response BioPharma, Inc. (1) · Merck KGaA, Darmstadt, Germany (1)
United States (5) · France (2) · Belgium (1) · Czechia (1) · Hungary (1) · Poland (1) · Slovakia (1) · United Kingdom (1)
Phil Breitfeld, MD (2) · Alice Bexon, MD (1) · Dr. Jean-Pierre Delord (1) · Philip Breitfeld, MD (1) · Richard Bartholomew, PhD (1)